This activity has expired. CME/CE credit is no longer available and the following content may not be available or may not be up-to-date. For a list of current activities that offer CME/CE credit, click here.

Printer-Friendly Email Page
Start the program at
the bottom of this page

Studies in Contrast MRI: Optimizing Patient Management and Imaging
Edition 1: Nephrogenic Systemic Fibrosis--Screening Strategies and Contrast Administration Policies

Release Date: February-27-12
Credit Expiration Date: February-27-13
Medium
Radiologists and other health care professionals interested or involved in diagnostic imaging and its role in patient diagnosis and management.

Attention radiologic technologists: This activity is approved by ASRT for 0.5 Category A+ continuing education credit. To access this version of the activity, please click here.
Credit Hours
Estimated amount of time to complete: 30 minutes
Medium
i-Newsletter
Program Description
Since the introduction of gadolinium-based contrast agents (GBCAs) into magnetic resonance imaging (MRI) in the 1980s, multiple contrast agents have been introduced and used extensively in a wide range of indications, particularly central nervous system (CNS) examinations, evaluation of neurodegenerative disease, and assessment of tumors. Contrast enhancement provides improved tissue contrast and characterization of lesions and more sensitive detection of smaller lesions. GBCAs differ in physicochemical characteristics and function, and their stability, concentration, and relaxivity can have a significant impact on their efficacy and safety in clinical applications.

Since 2006, GBCAs have been associated with a serious medical condition called nephrogenic systemic fibrosis (NSF). Much debate has centered on the available approved contrast agents and their chemical structure and stability in relation to their use in patients with renal impairment. Guidelines and recommendations for administering contrast to these patients have evolved, and with the continued development of contrast agents and imaging techniques, the characteristics and differences between the GBCAs have become more significant in imaging decisions.
Learning Objectives
Upon completion of this educational activity, the participant should be able to:
1.
Review the impact of nephrogenic systemic fibrosis on contrast MRI.
2.
Determine when a patient with renal disease may be at risk for NSF with GBCA administration.
3.
Discuss practical considerations for administering contrast media in patients with renal insufficiency.
faculty
Neil Rofsky, MD
Professor and Chairman
Effie and Wofford Cain Distinguished Chair in Diagnostic Imaging
Department of Radiology
UT Southwestern Medical Center
Dallas, TX

James Provenzale, MD
Department of Radiology
Division of Neuroradiology
Duke University Medical Center
Durham, NC

Mark Beautz, RT (R) (MR)
Chief Technologist / Magnetic Resonance Imaging Center
Duke University Medical Center
Durham, NC
faculty
It is the policy of Temple University School of Medicine; The Albert J. Finestone, MD Office for Continuing Medical Education to insure balance, independence, objectivity, and scientific rigor in all of its sponsored or jointly sponsored educational programs. All faculty, program planning committee members, and Temple University School of Medicine Continuing Medical Education staff participating in programs sponsored or jointly sponsored by Temple University School of Medicine are expected to disclose to the program audience any real or apparent conflict(s) of interest related to the content of their presentation(s).

Planning committee members have no financial relationships to disclose.

The information presented in this CME program represents the views and opinions of the individual contributors, and does not constitute the opinion or endorsement of, or promotion by, Temple University School of Medicine, Temple University Health System or its affiliates. Reasonable efforts have been taken intending for educational subject matter to be presented in a balanced, unbiased fashion and in compliance with regulatory requirements. However, each activity participant must always use his/her own personal and professional judgment when considering further application of this information, particularly as it may relate to patient diagnostic or treatment decisions including, without limitation, FDA-approved uses and any off-label uses.

Dr. Rofsky has no relevant financial relationships with any commercial interests to disclose.

Dr. Provenzale discloses that he receives grant/research support from GE Medical Healthcare and Bayer HealthCare Pharmaceuticals. He also serves as a consultant for Millennium and Theradex and is a stockholder in Amirsys, Inc.

Mr. Beautz has no relevant financial relationships with any commercial interests to disclose.
Credit Statements
Accreditation Statement: Temple University School of Medicine is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to sponsor Continuing Medical Education for physicians.

Certification Statement: Temple University School of Medicine designates this enduring activity for a maximum of 0.5 AMA PRA Category 1 CreditTM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

There is no fee to participate and receive credit.

Attention radiologic technologists: This activity is approved by ASRT for 0.5 Category A+ continuing education credit. To access this version of the activity, please click here.
Credit Provider Contact Information
Temple University
School of Medicine
The Albert J. Finestone, MD Office for CME
3500 North Broad Street Philadelphia, PA 19140
Phone: 215-707-4787
Fax: 215-707-8268
Commercial Support Statements
This educational activity is supported by an educational grant from Bayer HealthCare Pharmaceuticals.
Instructions
Minimum System Requirements: • Pentium III, 600 MHz or Equivalent Processor • 512 MB of RAM • Windows XP, Vista, or 7 • Mac OS X • 800x600 Monitor Resolution • 16-bit Color • 16 bit Sound Card with Speakers
1.
Please turn off all pop-up blockers to assure access to the educational activity.
2.
Click on the "Start program" icon at the bottom of this page. If you are not already registered as a user of this website, this will bring you to the login/registration page where you will be able to register as a new CMEcorner.com member or check existing registration information. When ready, click on the "Continue to Program" icon at the bottom of the screen.
3.
The next screen will permit you to check for or download the Flash player required to run this program and to begin the program presentation. The activity will take approximately 30 minutes to complete.
4.
After the activity has finished, click on the "Post-test" button.
5.
Instructions for completing and submitting the post-test and evaluation are provided on the post-test screen.
Certificate Fee

$0.00

Disclaimer
Copyright © 2012. Temple University School of Medicine. All rights reserved.

Presented by Temple University School of Medicine and Medical Communications Media, Inc.

The opinions expressed in this educational activity are those of the faculty and do not necessarily reflect the opinions or recommendations of their affiliated institutions, the publisher, Temple University School of Medicine, or Bayer HealthCare Pharmaceuticals. Any medications, diagnostic procedures, or treatments discussed by the program presenters should not be used by clinicians or other health care professionals without first evaluating their patients’ conditions, considering possible contraindications or risks, reviewing any applicable manufacturer’s product information, and comparing any therapeutic approach with the recommendations of other authorities.

To view our privacy policies, please visit: http://www.cmecorner.com/privacy.asp
Printer-Friendly Email Page Start Program as a Guest
Start Program
By clicking START PROGRAM I acknowledge that I have read the CME/CE information above.